Effectiveness of 177Lu-DOTATATE PRRT, n = 52
| Characteristic | Data |
|---|---|
| Cycles | |
| <4 | 9 (17) |
| 4 | 43 (83) |
| Dose | |
| Full | 49 (94) |
| Reduced | 3 (6) |
| MM best morphologic response | |
| ORR | 2 (4) |
| Stable disease | 50 (96) |
| Non-MM best morphologic response | |
| ORR | 4 (8) |
| Stable disease | 44 (90) |
| Progressive disease | 1 (2) |
| MM best metabolic response | |
| ORR | 0 (0) |
| Stable disease | 52 (100) |
| Non-MM best metabolic response | |
| ORR | 6 (12) |
| Stable disease | 43 (88) |
| MM-related symptom clinical response | |
| Complete | 3/26 (11) |
| Partial | 9/26 (35) |
| Stability | 14/26 (54) |
| Progression | 0/26 (0) |
| CS clinical response | |
| Complete or partial | 18 (46) |
| Stability | 19 (49) |
| Progression | 0 (0) |
| Not available | 2 (5) |
| MM-related symptom long-term clinical response | |
| Complete | 3 (11) |
| Partial | 8 (31) |
| Stability | 8 (31) |
| Progression | 3 (11) |
| Missing data | 4 (16) |
| MM-related PFS (mo) | Not reached |
| Non-MM PFS (mo) | 50.3 (38.2–61.7) |
| Overall survival (mo) | 55.0 (39.5–80.8) |
Categoric data are number or number per subpopulation, with percentage in parentheses. Continuous data are median, with 95% CI range in parentheses.